Stéphane Bancel is a French billionaire businessman and the CEO of Moderna Therapeutics, a clinical stage biotechnology company.
Bancel joined Moderna’s board of directors in 2011, the same year he was brought on as CEO. The biotech company focuses on the discovery and development of messenger RNA therapeutics and vaccines for infectious, immuno-oncology and cardiovascular diseases.
With Bancel at the helm during the COVID-19 global pandemic, Moderna was one of the first two vaccine developers to receive authorization in the United States. Moderna’s stock price rose in response to the success of the world’s first mRNA vaccine, making Bancel’s stake in the company worth over $1 billion.
Prior to Moderna, Bancel was the CEO of French diagnostics company, bioMérieux, from 2007 to 2011. While leading the company, he accelerated bioMérieux’s sales growth rate by pivoting to high-value biomarkers, as well as nearly doubling its market capitalization despite the financial crisis.
He gained experience in the pharmaceutical industry through roles at Eli Lilly including managing director, Belgium and executive director, global manufacturing strategy and supply chain.
Bancel was elected one of the World Economic Forum’s Young Global Leaders in 2009, Best CEO for Investor Relations in France in 2009, and #1 CEO in the biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.
Bancel sits on the boards of Qiagen N.V. and Indigo, and he is a venture partner at Flagship Pioneering as well as a trustee for Boston’s Museum of Science. He earned his master of engineering degree at École Centrale Paris, his M.S. in chemical engineering at the University of Minnesota, and his M.B.A. at Harvard Business School.
What is Stephane Bancel's net worth?
The estimated net worth of Stephane Bancel is at least $213.18 million as of June 28th, 2023. Mr. Bancel owns 5,411,946 shares of Moderna stock worth more than $213,176,553 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Bancel may own. Additionally, Mr. Bancel receives an annual salary of $4,550,000.00 as Chief Executive Officer at Moderna. Learn More about Stephane Bancel's net worth.
How old is Stephane Bancel?
What is Stephane Bancel's salary?
How do I contact Stephane Bancel?
Has Stephane Bancel been buying or selling shares of Moderna?
Stephane Bancel has not been actively trading shares of Moderna in the last ninety days. Most recently, Stephane Bancel sold 27,155 shares of the business's stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $121.63, for a transaction totalling $3,302,862.65. Following the completion of the sale, the chief executive officer now directly owns 5,411,946 shares of the company's stock, valued at $658,254,991.98. Learn More on Stephane Bancel's trading history.
Who are Moderna's active insiders?
Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (Chief Executive Officer), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.
Are insiders buying or selling shares of Moderna?
During the last year, insiders at the sold shares 49 times. They sold a total of 647,813 shares worth more than $81,384,380.50. The most recent insider tranaction occured on December, 9th when insider Shannon Thyme Klinger sold 529 shares worth more than $23,635.72. Insiders at Moderna own 15.7% of the company.
Learn More about insider trades at Moderna. Information on this page was last updated on 12/9/2024.